Targeting ROS1 rearrangements in non-small cell lung cancer with crizotinib and other kinase inhibitors

The discovery of molecular subtypes of non-small cell lung cancer (NSCLC) with oncogenic driver mutations and translocations/rearrangements has led to successful development of targeted therapies and improvement in outcomes of advanced lung cancer patients.